In fact, while in 2014 Velcheti and colleagues [35] stated that higher PD-L1 expression led to higher effectiveness of ICIs, LCMC3, and NEOSTAR showed treatment response in both PD-L1 positive and negative NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.